Amlodipine Treatment Reduces Stroke Size in Apolipoprotein E-Deficient Mice

American Journal of Hypertension

Volumn 19, Issue 11, 2006, Pages 1144-1149

  Mogi, Masaki ^a   Iwai, Masaru ^a   Chen, Rui ^a   Iwanami, Jun ^a   Ide, Ayumi ^a   Tsukuda, Kana ^a   Yoshii, Toyofumi ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

calcium channel blocker; cerebral blood flow; oxidative stress; Stroke

Indexed keywords

AMLODIPINE; APOLIPOPROTEIN E; HYDROETHIDINE; SUPEROXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; LASER DOPPLER FLOWMETRY; MALE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; STROKE;

AMLODIPINE; ANIMALS; APOLIPOPROTEINS E; BRAIN ISCHEMIA; CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; CHOLESTEROL; DIET; INFARCTION, MIDDLE CEREBRAL ARTERY; LASER-DOPPLER FLOWMETRY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATIVE STRESS; SUPEROXIDES;

EID: 33750380227     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.04.009     Document Type: Article

References (28)

1. Warlow C., Sudlow C., Dennis M., Wardlaw J., and Sandercock P. Stroke. Lancet 362 (2003) 1211-1224
2. ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Am Med Assoc 288 (2002) 2981-2997
3. Opie L.H. Calcium channel blockers in hypertension: reappraisal after new trials and major meta-analyses. Am J Hypertens 14 (2001) 1074-1081
4. Pitt B., Byington R.P., Furberg C.D., Hunninghake D.B., Mancini G.B., Miller M.E., Riley W., and PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 102 (2000) 1503-1510
5. Meir K.S., and Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 24 (2004) 1006-1014
6. Jawien J., Nastalek P., and Korbut R. Mouse models of experimental atherosclerosis. J Physiol Pharmacol 55 (2004) 503-517
7. Laskowitz D.T., Sheng H., Bart R.D., Joyner K.A., Roses A.D., and Warner D.S. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J Cereb Blood Flow Metab 17 (1997) 753-758
8. Hatcher J.P., Virley D., Hadingham S.J., Roberts J., Hunter A.J., and Parsons A.A. The behavioural effect of middle cerebral artery occlusion on apolipoprotein-E deficient mice. Behav Brain Res 131 (2002) 139-149
9. Hata R., Mies G., Wiessner C., Fritze K., Hesselbarth D., Brinker G., and Hossmann K.A. A reproducible model of middle cerebral artery occlusion in mice: hemodynamic, biochemical, and magnetic resonance imaging. J Cereb Blood Flow Metab 18 (1998) 367-375
10. Bederson J.B., Pitts L.H., Germano S.M., Nishimura M.C., Davis R.L., and Bartkowski H.M. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17 (1986) 1304-1308
11. Huang Z., Huang P.L., Panahian N., Dalkara T., Fishman M.C., and Moskowitz M.A. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science 265 (1994) 1883-1885
12. Connolly Jr. E.S., Winfree C.J., Springer T.A., Naka Y., Liao H., Yan S.D., Stern D.M., Solomon R.A., Gutierrez-Ramos J.C., and Pinsky D.J. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 97 (1996) 209-216
13. Szocs K., Lassegue B., Sorescu D., Hilenski L.L., Valppu L., Couse T.L., Wilcox J.N., Quinn M.T., Lambeth J.D., and Griendling K.K. Upregulation of Nox-based NAD(P)H oxidases in restenosis after carotid injury. Arterioscler Thromb Vasc Biol 22 (2002) 21-27
14. Iwai M., Liu H.W., Chen R., Ide A., Okamoto S., Hata R., Sakanaka M., Shiuchi T., and Horiuchi M. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 110 (2004) 843-848
15. Gotoh O., Mohamed A.A., McCulloch J., Graham D.I., Harper A.M., and Teasdale G.M. Nimodipine and the haemodynamic and histopathologic consequences of middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 6 (1986) 321-331
16. Orekhov A.N., Tertov V.V., and Pivovarova E.M. The effects of antihypertensive agents on atherosclerosis-related parameters of human aorta intimal cells. Cardiology 89 (1998) 111-118
17. Munro E., Patel M., Chan P., Betteridge L., Gallagher K., Schachter M., Wolfe J., and Sever P. Effect of calcium channel blockers on the growth of human vascular smooth muscle cells derived from saphenous vein and vascular graft stenoses. J Cardiovasc Pharmacol 23 (1994) 779-784
18. Yoshii T., Iwai M., Li Z., Chen R., Ide A., Fukunaga S., Oshita A., Mogi M., Higaki J., and Horiuchi M. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 29 (2006) 457-466
19. Trochu J.N., Bouhour J.B., Kaley G., and Hintze T.H. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res 87 (2000) 1108-1117
20. Wang Y.X., Halks-Miller M., Vergona R., Sullivan M.E., Fitch R., Mallari C., Martin-McNulty B., da Cunha V., Freay A., Rubanyi G.M., and Kauser K. Increased aortic stiffness assessed by pulse wave velocity in apolipoprotein E-deficient mice. Am J Physiol Heart Circ Physiol 278 (2000) H428-H434
21. Abernethy D.R. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology 80 Suppl 1 (1992) 31-36
22. Nissen S.E., Tuzcu E.M., Libby P., Thompson P.D., Ghali M., Garza D., Berman L., Shi H., Buebendorf E., and Topol E.J. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J Am Med Assoc 292 (2004) 2217-2225
23. Mason R.P., Leeds P.R., Jacob R.F., Hough C.J., Zhang K.G., Mason P.E., and Chuang D.M. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem 72 (1999) 1448-1456
24. Zhang X.P., Loke K.E., Mital S., Chahwala S., and Hintze T.H. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J Cardiovasc Pharmacol 39 (2002) 208-214
25. Endres M., Laufs U., Liao J.K., and Moskowitz M.A. Targeting eNOS for stroke protection. Trends Neurosci 27 (2004) 283-289
26. Dietrich W.D., Prado R., Pravia C., Zhao W., Ginsberg M.D., and Watson B.D. Delayed hypovolemic hypotension exacerbates the hemodynamic and histopathologic consequences of thromboembolic stroke in rats. J Cereb Blood Flow Metab 19 (1999) 918-926
27. Li J.M., Iwai M., Cui T.X., Min L.J., Tsuda M., Iwanami J., Suzuki J., Mogi M., and Horiuchi M. Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells. Mol Pharmacol 67 (2005) 1666-1673
28. 1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice. J Hypertens 23 (2005) 1383-1389